Previous 10 | Next 10 |
RALEIGH, N.C., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT) a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced its intent to present at the BIO CEO & Investor Conference tak...
CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal...
Preliminary top-line data from the alcoholic steatohepatitis (ASH) collaboration with Massachusetts General Hospital shows positive effect of larazotide on ethanol-induced permeability in vitro RALEIGH, N.C., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals Inc ...
RALEIGH, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Innovate) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced it intends to present at the BIO-Europe C...
RALEIGH, N.C., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced it intends to present at ...
Red Hat (NYSE: RHT ) +49% on being acquired by IBM. More news on: Red Hat, Inc., Diana Containerships Inc., China Recycling Energy Corporation, Stocks on the move, , Top stock market news, Read more ...
Micro cap Innovate Biopharmaceuticals (NASDAQ: INNT ) is up 12% premarket on modest volume on the heels of its announcement of encouraging preclinical data on lead candidate larazotide acetate in a mouse NASH model. The data showed a positive effect on reducing gut barrier perm...
Top line results showed larazotide having a significant effect on intestinal permeability, a mechanism thought to be key for bacterial translocation leading to NAFLD/NASH Further preclinical data in combination with approved drugs in development for NASH liraglutide (VICTOZA ® ) ...
RALEIGH, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, plans to host an event on Thursday, September 6, 2018, in New York fr...
Gainers: MNKD +57% . NCTY +29% . TA +29% . REPH +21% . CADC +20% . CDZI +18% . KNSA +16% . EPIX +15% . INNT +14% . NBEV +13% . More news on: MannKind Corporation, The9 Limited, TravelCenters of America LLC, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Innovate Biopharmaceuticals Inc. Company Name:
INNT Stock Symbol:
NASDAQ Market:
Innovate Biopharmaceuticals Inc. Website:
Completes concurrent financing of ~$22 million led by Orbimed Advisors, LLC Lead program, a proprietary long-acting GLP-1 receptor agonist, starting Phase 2 trial for Short Bowel Syndrome (SBS), an underserved, orphan condition Continued Phase 3 trial of larazotide; first and on...
RALEIGH, NC / ACCESSWIRE / March 20, 2020 / Innovate Biopharmaceuticals, Inc. (the "Company" or "Innovate") (NASDAQ:INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that it has filed its 2019 Annual Report on Form...
Israeli Regulatory Approvals Appear on Track for Late March 2020 to Allow Closing of the Merger RALEIGH, NC / ACCESSWIRE / March 11, 2020 / Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune a...